Clinical Study on Short-Term Survival Benefit of Osimertinib Sequential and Gefitinib in the Treatment of EGFR Mutant Advanced Non-Small Cell Lung Cancer
Objective:To investigate the effect of osimertinib sequential and gefitinib on short-term survival in patients with epidermal growth factor receptor(EGFR)mutant advanced non-small cell lung cancer(NSCLC).Methods:A total of 150 patients with EGFR mutant advanced NSCLC,who developed resistance to gefitinib and admitted to a hospital from July 2017 to July 2022,were retrospectively collected as study subjects.Patients received sequential osimertinib treatment were assigned to the sequential group(n=78),while those received gefitinib treatment were assigned to the control group(n=72).The control group received gefitinib tablets and the sequential group received osimertinib mesylate tablets.Both groups were treated for 3 courses of treatment.The clinical efficacy,levels of tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),carbohydrate antigen 199(CA199)],quality of life[quality of life core questionnaire-30(QLQ-C30)]and the occurrence of adverse reactions were compared between the two groups.Results:After treatment,the sequential group exhibited higher overall response rate and survival rate compared to the control group(P<0.05).The levels of serum CEA,CA125 and CA199 in both groups decreased(P<0.05),with the sequential group showing lower levels than the control group(P<0.05).The functional score of QLQ-C30 increased in both groups(P<0.05),with the sequential group exhibiting higher scores than the control group(P<0.05).The symptom score of QLQ-C30 was lower in both groups(P<0.05),with the sequential group showing lower scores than the control group(P<0.05).There were no significant differences in the incidence of alopecia,leukopenia,gastrointestinal symptoms and abnormal liver and kidney function between the two groups(P>0.05).Conclusion:Osimertinib sequential gefitinib in the treatment of EGFR mutant advanced NSCLC patients demonstrates significant clinical efficacy,effectively reducing the levels of serum tumor markers and improving the quality of life of patients.
万方数据
维普
